Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
PTC Therapeutics ( (PTCT) ) has provided an update.
On May 7, 2026, PTC Therapeutics reported first-quarter 2026 revenue of $273 million, driven by $226 million in product sales and strong momentum from the global launch of Sephience, which generated $125 million and 36% quarter-over-quarter growth. Despite a small net loss of $2.8 million versus prior-year profit boosted by one-time collaboration revenue, the company raised its 2026 product revenue guidance to $750–$850 million, underscoring confidence in its commercial trajectory amid mixed trends in legacy products and continued royalty growth from Evrysdi.
Operationally, PTC highlighted positive April 2026 topline data from the 24‑month PIVOT‑HD extension study of votoplam, supporting the ongoing global Phase 3 INVEST‑HD trial led by Novartis and triggering a $50 million milestone in the second quarter when the first patient was dosed. The company also outlined regulatory progress for vatiquinone in Friedreich’s ataxia, planning an open-label registration study in the third quarter of 2026 based on recent FDA feedback, positioning its pipeline for potential future approvals while maintaining substantial cash reserves of $1.89 billion at March 31, 2026.
The most recent analyst rating on (PTCT) stock is a Buy with a $120.00 price target. To see the full list of analyst forecasts on PTC Therapeutics stock, see the PTCT Stock Forecast page.
Spark’s Take on PTCT Stock
According to Spark, TipRanks’ AI Analyst, PTCT is a Neutral.
The score is driven by a sharp improvement in profitability and free cash flow plus constructive 2026 guidance and strong Sephience launch execution, partially offset by elevated balance-sheet risk (negative equity) and weak technical momentum (price below key moving averages with bearish indicators). Valuation is supportive due to a low P/E, but durability of earnings and revenue growth remains a key swing factor.
To see Spark’s full report on PTCT stock, click here.
More about PTC Therapeutics
PTC Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for rare genetic disorders, including neuromuscular and neurological diseases. Its commercial portfolio includes therapies such as Sephience for phenylketonuria, Translarna and Emflaza for Duchenne muscular dystrophy, and royalties from Evrysdi for spinal muscular atrophy, with an expanding global market presence.
Average Trading Volume: 1,140,680
Technical Sentiment Signal: Buy
Current Market Cap: $5.52B
For detailed information about PTCT stock, go to TipRanks’ Stock Analysis page.